Cited 4 times in
The Prognostic Value of 18F-FDG Uptake in the Supraclavicular Lymph Node (N3c) on PET/CT in Patients With Locally Advanced Breast Cancer With Clinical N3c
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김동우 | - |
dc.contributor.author | 김주흥 | - |
dc.contributor.author | 박형석 | - |
dc.contributor.author | 윤미진 | - |
dc.contributor.author | 조호진 | - |
dc.date.accessioned | 2019-12-18T01:22:04Z | - |
dc.date.available | 2019-12-18T01:22:04Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0363-9762 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/173486 | - |
dc.description.abstract | PURPOSE: We investigated the prognostic value of F-FDG uptake in the supraclavicular lymph node (SCLN) on PET/CT in breast cancer patients with clinical ipsilateral SCLN metastasis (cN3c). METHODS: Fifty-five female patients with initial F-FDG PET/CT were treated with curative intent. For semiquantitative analysis, the SUVmax of the primary tumor, axillary lymph node, and SCLN were normalized by the SUVmean of the liver (defined as SUVR-tumor, SUVR-axillary lymph node, and SUVR-SCLN, respectively). Cox proportional hazards models were used to predict disease-free survival (DFS) and overall survival (OS). Differences in DFS and OS were assessed by Kaplan-Meier analysis. RESULTS: Twenty-three patients (41.8%) experienced recurrence, and 13 (23.6%) died during follow-up (median, 70.0 months; range, 6-128 months). In multivariate analysis, SUVR-tumor greater than 3.26 (hazards ratio, 7.26; 95% confidence interval, 1.58-33.31; P = 0.01) and SUVR-SCLN greater than 1.05 (hazards ratio, 8.47; 95% confidence interval, 1.09-65.87; P = 0.04) were prognostic for OS. No clinicopathologic or PET/CT parameters were prognostic for DFS. The patients were divided into 3 groups: group 1 (n = 11, SUVR-tumor ≤3.26 and SUVR-SCLN ≤1.05); group 2 (n = 27, SUVR-tumor >3.26 or SUVR-SCLN >1.05); and group 3 (n = 17, SUVR-tumor >3.26 and SUVR-SCLN >1.05). The 5-year OS rates were 100% in group 1, 85.2% in group 2, and 51.0% in group 3. Group 3 showed worse prognosis than group 1 (P < 0.01) and group 2 (P < 0.01). CONCLUSIONS: In addition to SUVR-tumor, SUVR-SCLN seemed to play an important role in selecting patients with the worst prognosis. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Lippincott | - |
dc.relation.isPartOf | CLINICAL NUCLEAR MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Biological Transport | - |
dc.subject.MESH | Breast Neoplasms/diagnostic imaging* | - |
dc.subject.MESH | Breast Neoplasms/metabolism* | - |
dc.subject.MESH | Breast Neoplasms/pathology | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorodeoxyglucose F18/metabolism* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymph Nodes/metabolism* | - |
dc.subject.MESH | Lymph Nodes/pathology | - |
dc.subject.MESH | Lymphatic Metastasis | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Positron Emission Tomography Computed Tomography* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | The Prognostic Value of 18F-FDG Uptake in the Supraclavicular Lymph Node (N3c) on PET/CT in Patients With Locally Advanced Breast Cancer With Clinical N3c | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Nuclear Medicine (핵의학교실) | - |
dc.contributor.googleauthor | Lee, Suk Hyun | - |
dc.contributor.googleauthor | Kim, Sung Hoon | - |
dc.contributor.googleauthor | Park, Hyung Seok | - |
dc.contributor.googleauthor | Kim, Joo Heung | - |
dc.contributor.googleauthor | Kim, Dongwoo | - |
dc.contributor.googleauthor | Cho, Hojin | - |
dc.contributor.googleauthor | Yun, Mijin | - |
dc.identifier.doi | 10.1097/RLU.0000000000002365 | - |
dc.contributor.localId | A05304 | - |
dc.contributor.localId | A04910 | - |
dc.contributor.localId | A01753 | - |
dc.contributor.localId | A02550 | - |
dc.contributor.localId | A03941 | - |
dc.relation.journalcode | J00595 | - |
dc.identifier.eissn | 1536-0229 | - |
dc.identifier.pmid | 30540598 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00003072-201901000-00030&LSLINK=80&D=ovft | - |
dc.contributor.alternativeName | Kim, Dongwoo | - |
dc.contributor.affiliatedAuthor | 김동우 | - |
dc.contributor.affiliatedAuthor | 김주흥 | - |
dc.contributor.affiliatedAuthor | 박형석 | - |
dc.contributor.affiliatedAuthor | 윤미진 | - |
dc.contributor.affiliatedAuthor | 조호진 | - |
dc.citation.volume | 44 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | e6 | - |
dc.citation.endPage | e12 | - |
dc.identifier.bibliographicCitation | CLINICAL NUCLEAR MEDICINE, Vol.44(1) : e6-e12, 2019 | - |
dc.identifier.rimsid | 64377 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.